Shinil Pharmaceutical신일제약
012790 · KOSDAQ · ₩012790 · 신일제약
₩6,340▲ ₩20 (0.32%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩81B | ₩89B | ₩89B | ₩80B | ₩62B |
| Cost of sales | ₩47B | ₩49B | ₩52B | ₩44B | ₩37B |
| Gross profit | ₩33B | ₩41B | ₩38B | ₩36B | ₩24B |
| Operating income | ₩7.4B | ₩15B | ₩14B | ₩14B | ₩8B |
| Net income | ₩7.5B | ₩14B | ₩14B | ₩12B | ₩6.7B |
| Net income to shareholders | ₩7.5B | ₩14B | ₩14B | ₩12B | ₩6.7B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩169B | ₩166B | ₩152B | ₩143B | ₩129B |
| Current assets | ₩83B | ₩77B | ₩69B | ₩67B | ₩58B |
| Cash and equivalents | ₩9.3B | ₩4.6B | ₩7.5B | ₩4.9B | ₩7.3B |
| Total liabilities | ₩17B | ₩19B | ₩18B | ₩20B | ₩16B |
| Current liabilities | ₩15B | ₩16B | ₩14B | ₩16B | ₩12B |
| Total equity | ₩152B | ₩147B | ₩135B | ₩123B | ₩113B |
| Shareholders' equity | ₩152B | ₩147B | ₩135B | ₩123B | ₩113B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩12B | ₩23B | ₩15B | ₩14B | ₩11B |
| Capital spending | ₩3.1B | — | — | — | — |
| Free cash flow | ₩8.5B | ₩23B | ₩15B | ₩14B | ₩11B |
| Dividends paid | ₩2.2B | ₩2B | ₩1.1B | ₩1.1B | ₩1.1B |
Consolidated where available. Amounts in won.
Also known as: Shinil Pharmaceutical / 신일제약 / 012790 / KRX:012790
Source: KRX statistical information